Durham pharma pushing to fight a common cold virus that's deadly to some patients
For Durham-based Chimerix (Nasdaq: CMRX), fighting a virus known to cause the common cold is not a task it takes lightly.
That's because the company is currently setting up sites for a Phase 2 clinical trial of its lead antiviral drug brincidofovir for the treatment of adenovirus in pediatric transplant patients.
While the common virus is typically treated with over-the-counter medications, for patients with a w eakened immune system – such as pediatric transplant patients – it can be very…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Jennifer Henderson Source Type: news
More News: Adenoviruses | American Health | Clinical Trials | Common Cold | Health Management | Pediatrics | Pharmaceuticals | Transplants